Cochlear (ASX:COH) posts profit of $289 million but highlights hospital wait times

On Friday, Cochlear reported record sales of $1.64 billion for 2022, up 10 percent year-on-year amid strong demand for hearing implants and sound processors.

Total sales of implants increased by 5 percent over the year. Howitt said the company expects underlying earnings to rise 5 to 10 percent in 2023, with hopes of cashing in between $290 million and $305 million.

The second half of next year is expected to boost those gains, but given the restrictions on “intermittent COVID-related hospital or region-specific elective surgeries” are still expected in the next six months.

The company also unveiled an emissions reduction plan on Friday that aims to achieve net-zero carbon emissions by 2030 across its operations and across its entire value chain by 2050.

Investors will see a final dividend of $1.45, up 4 percent year-over-year, and a total payout of $3.00 per share for the full year.

RBC Capital has a price target of $154 for the stock, well below the share price it was trading at on Friday.

Analyst Craig Wong-Pan said revenue came in ahead of guidance, “however, earnings at an EBITDA, EBIT and NPAT level were slightly below RBC and consensus expectations at 2-3%.”

Cochlear shares rose over 4 percent during Friday’s session before closing 2.2 percent higher at $218.86.

The Market Recap Newsletter is a summary of the trading day. Get it every afternoon on weekdays. Cochlear (ASX:COH) posts profit of $289 million but highlights hospital wait times

Brian Lowry

InternetCloning is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button